


# Two New Sigma-1 Leads Discovered by Scaffold-Hopping

Christopher W. Cunningham,<sup>1</sup> Anghelo J. Gangano<sup>1</sup>, Savanah L. Saldaña-Shumaker<sup>1</sup> <sup>1</sup>Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI USA


## Introduction

- “Scaffold-hopping” is a drug design strategy based on the idea that replacing one core scaffold with a structurally related group will maintain pharmacologic activity at a given target.
- We found that 3-aminopyrrolidines CWC-1-001 (**1**) and CWC-1-002 (**2**) bind dopamine 4 (D4R) receptors with preferential binding over D1-3R (**Figure 1A**).
- Hypothesis:** we can “hop” from 3-aminopyrrolidine to piperazine without compromising D4R binding affinity and selectivity.



**Figure 1:** A) Structures of **1** and **2**, with their proposed advantages and disadvantages for drug design. B) The 3-aminopyrrolidine (green) and piperazine (blue) core scaffolds share a similar N-N distance of 2.9 Å.

## Synthesis




**Scheme 1:** Synthesis of **2a** and **2b**. Reagents and conditions: a) 4-Bromophenylisocyanate, NEt<sub>3</sub> (2.2 equiv.), THF, RT, 18 hr, 77%. b) 2-Naphthoyl chloride (1.1 equiv.) NEt<sub>3</sub> (2.2 equiv.), THF, RT, 18 hr, 83%. c) Benzyl bromide (1.1 equiv.), DCM, RT, 18 hr, > 90%. Final product verification was completed using <sup>1</sup>H, <sup>13</sup>C NMR, HSQC, gCOSY, MS, HPLC, melting point.

## Results

|           | D1       | D2       | D3       | D4  | D1/D4 | D3/D4 | σ1  | σ2       | σ2/σ1 | Other (Ki < 100 nM)                  |
|-----------|----------|----------|----------|-----|-------|-------|-----|----------|-------|--------------------------------------|
| <b>1</b>  | > 10,000 | > 10,000 | 1083     | 20  | > 500 | 54    | 50  | 176      | 3.5   | 5-HT2B (23)                          |
| <b>1b</b> | > 10,000 | > 10,000 | > 10,000 | 205 | > 49  | > 49  | 14  | > 10,000 | > 714 |                                      |
| <b>2</b>  | 1977     | 1136     | 322      | 6.5 | 304   | 50    | 15  | 71       | 4.7   | 5-HT1A (28), 5-HT2B (4), 5-HT2C (62) |
| <b>2b</b> | > 10,000 | > 10,000 | 528      | 445 | 23    | 1.2   | 5.1 | 4113     | 806   |                                      |

**Table 1:** Binding data for novel compounds. Data courtesy of the NIMH Psychoactive Drug Screening Program (PDSP). Data are shown as Ki in nM.



**Figure 3:** Docking within σ1 receptor. **A)** Global view of σ1 (pdsp 5HK2). **B)** Zoom-in on the σ1 binding pocket. **C)** Overlap of low-energy docked poses compared to co-crystallized 4-IBP (green): **i)** re-docked 4-IBP (magenta), **ii)** **1b** (yellow), **iii)** **2b**. (*Nature* 2016, 532: 527-530. *Mol. Neurobiol.* 2014, 50: 149-158. *J. Comput. Chem.* 2010, 31: 455-461)

## Conclusions

- “Hopping” from 3-aminopyrrolidine to piperazine lowered affinity for dopamine receptors.
- 3-Aminopyrrolidines are “σ1-preferring” and piperazines are “σ1-selective” (Ki ratio > 700).
- Off-target 5-HT<sub>1,2</sub>R activity greatly diminished.
- CWC-1-024 (**1b**) and CWC-1-025 (**2b**) are new leads for treating neuropsychiatric disorders, substance use disorder, and pain.

## Acknowledgements

- AJG was supported by a Summer Undergraduate Research Fund (SURF) award.
- CWC is supported by the Department of Pharmaceutical and Administrative Sciences.